Replimune Group Inc

Quantli Newsdesk

· 18 days ago

Replimune announced that the FDA accepted its resubmitted Biologics License Application for RP1 combined with nivolumab to treat advanced melanoma. The FDA classified this as a complete, class 1 response with a review target date of August 2, 2026, and scheduled an advisory committee meeting for late July.